TGTiankang Guo

Tiankang Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tiankang Guo has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Junliang Li

    Gansu University of Chinese Medicine Lanzhou China

    3 shared publications
  • Bo Chen

    Department of Ultrasound Diagnosis, Gansu Provincial Hospital, Lanzhou, Gansu, China

    1 shared publication
  • Cheng Chen

    Department of Pathology, Gansu Provincial Hospital, Lanzhou, Gansu, China

    1 shared publication
  • Guolan Kang

    Department of Endoscopic Center, Gansu Provincial Hospital, Lanzhou, China

    1 shared publication
  • Junliang Li

    The First School of Clinical Medicine of Lanzhou University, Lanzhou, Gansu, China; Department of General Surgical, Gansu Provincial Hospital, Lanzhou, Gansu, China; The First School of Clinical Medical, Gansu University of Chinese Medicine, Lanzhou, Gansu, China

    1 shared publication
  • Ruipeng Wang

    The First School of Clinical Medicine, Lanzhou University, Lanzhou 730030, China

    1 shared publication

Latest Publications

  • Feasibility of Enhanced Recovery After Surgery Protocols Implemented Perioperatively in Endoscopic Submucosal Dissection for Early Gastric Cancer: A Single-Center Retrospective Study

    by Junliang Li, Guolan Kang, Tianxiang Liu, Zongshu Liu, Tiankang Guo

    Background: Endoscopic submucosal dissection (ESD) for early gastric cancer (EGC) has advantages over traditional radical gastrectomy. We investigated whether enhanced recovery after surgery (ERAS) protocols are appropriate in the ESD perioperative period. Materials and Methods: We screened 129 consecutive patients, and 12 were excluded. All study patients underwent ESD for EGC. Of the 117 included patients, 57 received traditional perioperative care between January 2017 and December 2018, and 60 patients received perioperative care according to ERAS protocols between January 2019 and September 2020. The primary study endpoint was ESD-related complications. Secondary endpoints included the following postoperative parameters: anal exhaust time, incidence of nausea or vomiting, length of hospitalization, fever rate, abdominal pain on the visual analog scale (VAS), and reported perioperative satisfaction. Results: Complications were comparable between the 2 groups. In the ERAS group, no patients experienced delayed bleeding or perforation. One traditional group patient bled, and one perforated. Postoperative anal exhaust time, nausea or vomiting incidence, hospitalization, fever rate, and VAS pain scores were significantly lower, and perioperative satisfaction rate was significantly higher in the ERAS group. Conclusions: ERAS protocols are both feasible and safe for patients undergoing ESD. ERAS protocols enhance the advantages of ESD for EGC without increasing complications.


  • Open Access

    Mechanisms of Peritoneal Mesothelial Cells in Peritoneal Adhesion

    by Ruipeng Wang, Tiankang Guo, Junliang Li

    A peritoneal adhesion (PA) is a fibrotic tissue connecting the abdominal or visceral organs to the peritoneum. The formation of PAs can induce a variety of clinical diseases. However, there is currently no effective strategy for the prevention and treatment of PAs. Damage to peritoneal mesothelial cells (PMCs) is believed to cause PAs by promoting inflammation, fibrin deposition, and fibrosis formation. In the early stages of PA formation, PMCs undergo mesothelial–mesenchymal transition and have the ability to produce an extracellular matrix. The PMCs may transdifferentiate into myofibroblasts and accelerate the formation of PAs. Therefore, the aim of this review was to understand the mechanism of action of PMCs in PAs, and to offer a theoretical foundation for the treatment and prevention of PAs.


  • Open Access

    Role of Peritoneal Mesothelial Cells in the Progression of Peritoneal Metastases

    by Junliang Li, Tiankang Guo

    Peritoneal metastatic cancer comprises a heterogeneous group of primary tumors that originate in the peritoneal cavity or metastasize into the peritoneal cavity from a different origin. Metastasis is a characteristic of end-stage disease, often indicative of a poor prognosis with limited treatment options. Peritoneal mesothelial cells (PMCs) are a thin layer of cells present on the surface of the peritoneum. They display differentiated characteristics in embryonic development and adults, representing the first cell layer encountering peritoneal tumors to affect their progression. PMCs have been traditionally considered a barrier to the intraperitoneal implantation and metastasis of tumors; however, recent studies indicate that PMCs can either inhibit or actively promote tumor progression through distinct mechanisms. This article presents a review of the role of PMCs in the progression of peritoneum implanted tumors, offering new ideas for therapeutic targets and related research.